ProfileGDS5678 / 1451314_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 83% 81% 91% 84% 83% 82% 81% 80% 81% 82% 80% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7152481
GSM967853U87-EV human glioblastoma xenograft - Control 26.0955183
GSM967854U87-EV human glioblastoma xenograft - Control 35.7730881
GSM967855U87-EV human glioblastoma xenograft - Control 47.6256391
GSM967856U87-EV human glioblastoma xenograft - Control 56.2681784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.896483
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7179582
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.714981
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6854980
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8591881
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9384182
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7452280
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7607181
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9860882